Edition:
United Kingdom

Odonate Therapeutics Q4 Loss Per Share $1.17


Friday, 22 Feb 2019 

Feb 22 (Reuters) - Odonate Therapeutics Inc ::ODONATE THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2018.Q4 LOSS PER SHARE $1.17.AS OF DECEMBER 31, 2018, ODONATE HAD $139.1 MILLION IN CASH, COMPARED TO $198.1 MILLION AS OF DECEMBER 31, 2017..EXPECT TO COMPLETE ENROLLMENT IN PHASE 3 STUDY OF TESETAXEL IN PATIENTS WITH METASTATIC BREAST CANCER, IN H2 OF 2019.EXPECT TO REPORT TOP-LINE RESULTS FROM PHASE 3 STUDY OF TESETAXEL IN PATIENTS WITH METASTATIC BREAST CANCER IN 2020. 

Company Quote

32.35
-1.09 -3.26%
16 Aug 2019